April 23 - Europe’s drug regulator reiterated on Friday that
benefits of
AstraZeneca’s
COVID-19 vaccine outweigh any risks, as part of a
detailed guidance from ongoing reviews into rare blood clots to help individual
nations determine the shot’s use.
اضافة اعلان
The renewed backing comes after several countries in the
European Union and worldwide have limited the use of the vaccine, known as
Vaxzevria, while Denmark has stopped its use altogether, after possible links
to clotting issues were confirmed.
The interim analysis by a committee of the European
Medicines Agency (EMA) determined that serious side effects of rare blood clots
are likely to occur in 1 out of 100,000 vaccinated people, the regulator said
in a statement.
Earlier this month, the EMA said it had found a possible
link between AstraZeneca’s coronavirus vaccine and a similar, rare blood
clotting problem connected to the one from Johnson & Johnson which led to a
small number of deaths.
There was not enough data on Vaxzevria from Europe to
determine if blood clot risks with low blood platelets would differ with each
dose of the vaccine, or to provide context on its benefits and risks with
regards to sex, the EMA said.
Countries are also in the midst of determining whether to use
J&J’s vaccine over concerns of blood clots. Regulators have found these
events occurred mostly in the brain and abdomen.
Read more
Health
.jpg)
.jpg)
